In 2023, the mortality from trachea, bronchus, or lung malignant neoplasms in the US stood at approximately 127.00 thousand deaths. Forecasts suggest a declining trend from 2024 to 2028, with the data showing a consistent decrease in mortality each year. By 2028, the forecasted mortality is expected to be 111.81 thousand, illustrating a reduction in value over the observed period. The year-on-year variation indicates that the mortality rate is decreasing at an average annual rate, highlighting improved healthcare interventions and potentially more effective treatments or preventive measures.
Future trends to watch would include advancements in medical technology, public health policies focusing on smoking reduction, and the development of personalized medicine approaches. Further research into early detection and prevention strategies will likely continue to impact mortality rates positively.
